CORONA Remedies Limited Q2 FY26 results deck summary

Results deck of 3 Jan 2026, summarised by AI from the filing.

Q2 FY26 revenue ₹361.1 cr (+15.1%), PAT ₹52.3 cr (+21.8%); H1 FY26 revenue ₹707.7 cr (+17.0%)

Key takeaways

1. Q2 FY26 revenue Revenue ₹361.1 cr (Q2FY25: ₹313.9 cr, +15.1%)
2. Q2 FY26 PAT PAT ₹52.3 cr (Q2FY25: ₹43.0 cr, +21.8%)
3. H1 FY26 EBITDA EBITDA ₹148.3 cr (H1FY25: ₹116.3 cr, +27.4%)
4. Capacity addition Additional commercial production of 400 Mn tablets commenced on 22nd December 2025 at the Gujarat Facility

Original filing on BSE

CORONA Remedies Limited Q1 FY27 results

As filed: Revenue ₹422 cr, EBITDA ₹93.1 cr, PAT ₹60.1 cr, EBITDA margin 22.1%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹353 cr, EBITDA ₹62.0 cr, PAT ₹45.1 cr, EBITDA margin 17.6%. Not scored. No result for the same quarter last year. Share price after the results: −1.2% in 30 days (Nifty 500: −2.5%).
• Q3 FY26: Revenue ₹342 cr, EBITDA ₹83.2 cr, PAT ₹41.3 cr, EBITDA margin 24.3%. Not scored. No result for the same quarter last year. Share price after the results: +2.5% in 28 days (Nifty 500: −4.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

CORONA Remedies Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (3 Aug 2026), Results deck (31 Jul 2026), Results press release (31 Jul 2026)
• Q4 FY26: Earnings call (12 May 2026), Results deck (11 May 2026), Results press release (11 May 2026)
• Q3 FY26: Earnings call (3 Feb 2026), Results deck (2 Feb 2026), Results press release (2 Feb 2026)
• Q2 FY26: Earnings call (5 Jan 2026), Results deck (3 Jan 2026), Results press release (2 Jan 2026)